Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
170 hedge funds and large institutions have $300M invested in Antares Pharma, Inc. in 2021 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 70 increasing their positions, 42 reducing their positions, and 19 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 42
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 19
3% less call options, than puts
Call options by funds: $461K | Put options by funds: $477K
3% less funds holding
Funds holding: 175 → 170 (-5)
16% less capital invested
Capital invested by funds: $356M → $300M (-$56.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$2.22M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$2.02M |
| 3 |
TAM
Tocqueville Asset Management
New York
|
+$1.74M |
| 4 |
Russell Investments Group
London,
United Kingdom
|
+$1.41M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.18M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$3.07M |
| 3 |
Morgan Stanley
New York
|
-$2.38M |
| 4 |
BAS
Brown Advisory Securities
Baltimore,
Maryland
|
-$1.2M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$955K |
ATRS Hedge Fund Activity: Q3 2021 in Review
170 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q3 2021, worth a combined $300M — down 16% from $356M a quarter earlier.
Fund positioning in ATRS was balanced in Q3 2021: 19 funds opened new positions, 19 closed out, 70 added to existing stakes and 42 trimmed.
The largest buyer was Magnetar Financial, adding an estimated $2.22M. The largest seller was Fidelity Investments, cutting an estimated $8.18M.
- 170 institutional investors held Antares Pharma, Inc. (ATRS) as of Q3 2021, down from 175 in Q2 2021.
- Funds reported $300M of Antares Pharma, Inc. stock for Q3 2021, down 16% quarter-over-quarter.
- 19 funds opened new Antares Pharma, Inc. positions in Q3 2021 and 19 closed out, a net change of 0 holders.
- The largest Antares Pharma, Inc. buyer in Q3 2021 was Magnetar Financial, an estimated $2.22M added.
- The largest Antares Pharma, Inc. seller in Q3 2021 was Fidelity Investments, an estimated $8.18M sold.
Based on aggregated 13F filings for Q3 2021.